Hexo: Canaccord Lowers Price Target Following Poor Execution

On Monday, Hexo Corp (TSX: HEXO) (NYSE: HEXO) reported their fiscal third-quarter estimates which missed consensus estimates significantly. HEXO reported revenues of $22.7 million, a measly 2% increase year over year and a ~31% decrease quarter over quarter. Gross profit came in at $4.38 million, and had the same fate as revenue, cratering 61.3% quarter over quarter.

Many analysts have come out and lowered their targets and ratings on the company. ATB, Alliance, CIBC, Stifel-GMP, and Canaccord lowered their 12-month price targets bringing the consensus 12-month price target to C$8.43, down from C$9.47 from before the release. The company has 12 analysts covering the stock with three analysts having buy ratings, eight analysts have hold ratings and one analyst has a strong sell rating. The street high comes from Alliance Global with a C$12 price target while the lowest comes in at C$5.97.

In Canaccord’s note, they lowered their 12-month price target to C$7.00 from C$9.00 and reiterated their hold rating on the name. Matt Bottomley says that this quarter “represented a step back with respect to the company’s execution in its core legacy business,” even though the recent M&A puts the company in a top-three market share position.

For this quarter, the company reported revenues $10 million lower than Canaccord’s estimates. This is concerning to Bottomley due to the company seeing sales in its core market drop by $5.2 million and the company having issues with its production of hash products during the quarter. BUT the company boasted a leading market share of 46% in beverages!

Bottomley warns that the volatility in LP’s revenue might continue as “the saturated Canadian cannabis landscape continues to evolve,” and believes that this is a very high risk to the LP’s fundamentals.

Below you can see Canaccord’s updated full-year 2021 and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

First Majestic Tracking Ahead Of Guidance Following Q1 Production Results

Canadian Gold Drills 19.5 g/t Gold Over 1.0 Metre At Lac Arsenault

Related News

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Monday, October 18, 2021, 11:31:00 AM

Green Thumb: Analysts Anticipate Q1 Revenues Of US$187.4 Million

Green Thumb Industries (CSE: GTII) announced that they will be reporting their first quarter financials...

Wednesday, May 12, 2021, 11:06:00 AM

Ayr Wellness: Canaccord Reiterates Ratings After Quarterly Results

On August 16, Ayr Wellness (CSE: AYR.a) reported their second quarter financial results. The company...

Thursday, August 26, 2021, 10:24:00 AM

WeCommerce: TD, Canaccord Raise Price Targets After Leading Bought Deal

Last week, WeCommerce (TSXV: WE) announced that their bought deal closed. The company issued 2.81...

Friday, July 16, 2021, 04:09:00 PM

Trulieve: Five Analysts Raise Price Targets Following Stellar Earnings

Trulieve Cannabis (CSE: TRUL) reported their second-quarter financial results this week, boasting a record U$120.8...

Friday, August 14, 2020, 11:43:41 AM